Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXiaomei ChenChinese Academy of Medical Sciences & Peking Union Medical CollegeLHLisi HuangSun Yat-sen UniversityMLMinming LiGuangdong General Hospital

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows ABC-14 regimen leads to similar post-transplant outcomes in AML, highlighting potential as bridging therapy.

Key Points

  • Evaluate the effectiveness of the ABC-14 regimen as a bridging therapy to allogeneic hematopoietic stem cell transplantation in AML.
  • Retrospective analysis of 51 AML patients who underwent allo-HSCT.
  • Patients received either ABC-14 regimen or intensive chemotherapy prior to conditioning.
  • Primary outcomes included engraftment, viral infections, GVHD incidence, relapse, non-relapse mortality, and survival.
  • Successful engraftment in all patients with similar engraftment times for both cohorts.
  • ABC-14 showed no relapses observed, compared to 11.4% in IC cohort.
  • Rates of viral infections and non-relapse mortality were comparable between groups.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dbb5https://doi.org/10.1182/blood-2025-5991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial2025
  2. 2Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial2025
  3. 3Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia2025
  4. 4A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.2024 · 2 citations
  5. 5The efficacy and safety of venetoclax-based and anthracycline-free induction therapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of transplant-eligible Acute Myeloid Leukemia patients2025